Project Grant R43DA061666
Award Date
8/15/24
Completion Date
4/30/25
Dollars Obligated
$396K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
MIDDLE CITY EAST, PA 19102, USA
Similar Awards
This federal Project Grant award, valued at $2,187,775.00 and issued on August 1, 2024, was provided by the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant aims to develop novel selective positive allosteric modulators (PAMs) of the high-sensitivity α4β2 nicotinic acetylcholine receptor (nAChR) subtypes, which are believed to play a key role in behaviors associated with nicotine dependence. The research will focus on synthesizing and...
This $175,888 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop novel methods for studying the genetic and neurological mechanisms underlying nicotine and cannabis addiction. The key products and services to be delivered under this 4-year grant include: Developing a new Transcriptome-Wide Association Study (TWAS) method to identify genes associated with changes in brain functional connectivity...
This $181,675 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to investigate the cellular, synaptic, and molecular mechanisms by which nicotine exposure during prenatal development can influence the maturation of excitatory synapses in the prefrontal cortex. The research will utilize innovative techniques including two-photon uncaging of glutamate, chemogenetics, electrophysiology, and pharmacology to...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is providing $400,000 over 12 months to support Iontx Inc., a woman-owned small business, in advancing the development of a novel small-molecule modulator of the FGF13/NAV1.6 protein complex. This work aims to normalize nucleus accumbens activity as a potential treatment for cocaine use disorder (CUD), a critical public health issue lacking...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,536 in funding to Chemregen Inc. in San Diego, CA. The objective is to design, synthesize, and test non-opioid drug candidates to combat the opioid public health crisis, particularly the dangers of fentanyl. The award supports two specific aims: 1) Developing and characterizing lead compounds and control compounds for receptor binding and...
This $320,000 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop an innovative smoking and vaping cessation treatment. The project, led by Spacerx LLC, will explore the feasibility of delivering the smoking cessation drug candidate cytisine through electronic vape administration (EVA) to help stabilize dopamine levels and reduce nicotine self-administration in a mouse model of nicotine...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $3,257,011 to The Medical University of South Carolina to evaluate a tobacco harm reduction strategy among clients enrolled in substance use disorder (SUD) treatment. The study aims to assess whether switching to electronic nicotine delivery systems (ENDS) is more effective than using nicotine replacement therapy (NRT) in promoting...
This $982,800 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to leverage genome-wide and epigenome-wide association studies to better understand the relationship between nicotine metabolism, smoking cessation, and tobacco-related health outcomes in American Indian (AI) communities. The research project will be conducted by the University of Colorado-Denver and will involve a three-phased approach: 1)...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $275,253 to Epivario Inc. to develop a novel epigenetic regulator as a treatment for opioid use disorder (OUD). The award supports screening of next-generation compounds targeting the metabolic enzyme ACSS2, which has been shown to play a key role in the encoding of drug-related memories. This research aims to identify a potent ACSS2 inhibitor that...
This $610,092 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) is designed to develop and test a hybrid substance use prevention program for upper elementary school students. The program will utilize a combination of online e-learning modules and traditional classroom sessions to teach students about the harms of vaping and the importance of safe prescription medication use. It will also focus on enhancing...